What AndroFeme (Testosterone) Treats: Main Uses and Benefits

The purpose of AndroFeme is to provide hormone restoration for women with an underlying deficiency of endogenous testosterone. This therapy is considered relevant in clinical settings marked by increased patient discomfort caused by specific, persistent symptoms. The medication is applied across therapeutic domains, including the symptomatic management of Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.

The primary benefit is in providing supportive relief for symptom clusters that may become disruptive, such as a distressing loss of sexual desire, chronic fatigue, and diminished mental clarity. AndroFeme is applied in symptomatic contexts where systemic imbalance may contribute to symptoms that interfere with daily functioning. It is also commonly used when supportive symptom management is appropriate for symptoms that result from natural menopause, premature menopause, or surgical removal of the ovaries (oophorectomy), often as an adjunct to existing estrogen-based HRT.

---

Quick Fact: Relief for Distressing Sexual Symptoms AndroFeme is commonly used to help manage the primary symptom of Hypoactive Sexual Desire Disorder (HSDD), assisting with maintaining functional stability during symptomatic periods marked by a persistent lack of sexual desire and reduced arousal.

Regulatory References

1. Australian Government TGA Product Information

Eligibility Map: Who Can and Cannot Use AndroFeme (Testosterone)

---

Eligibility Scope

Populations for whom use is allowed: Adult Women, primarily Postmenopausal Women. Populations for whom use is contraindicated: Male patients; Pregnant or breastfeeding women; Patients with a history of androgen-dependent neoplasia (e.g., breast carcinoma); Patients with thromboembolism, nephrotic syndrome, or hypercalcaemia. Age-related eligibility rules: Contraindicated in children. Caution is advised for patients over 70 years of age. Safety and efficacy are not established in the pediatric population. Condition-specific eligibility rules: Use requires close monitoring in patients with pre-existing cardiac, hepatic (liver), or renal (kidney) diseases due to the potential for fluid retention. Pregnancy and lactation eligibility status: Both are absolute contraindications. Eligibility-related restrictions: Not recommended for women who still menstruate unless adequate contraceptive measures are utilized.

---

Eligibility Classifications (High-Level)

Eligibility severity classification: Contraindicated (Absolute prohibition: Cancer, Pregnancy, etc.); Not Recommended/Not Established (Pediatric use, use beyond 24 months); Caution/Monitoring Required (Organ disease). Regulatory basis: TGA (Australia) / Medsafe (New Zealand) Product Information and general Testosterone Class Warnings. Eligibility-context constraints: Restricted to the female population; Prohibited during pregnancy/lactation; Absolute exclusion for certain comorbidities.

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is contraindicated in patients with a history of breast cancer or any androgen-dependent neoplasia.
• Use is contraindicated during pregnancy and breastfeeding.
• Children are an explicitly contraindicated population.
• Patients with pre-existing cardiac, hepatic, or renal diseases require close monitoring when using the medicine.

Connection to the overall eligibility profile: Official regulatory documents define eligibility by licensing the product for use solely in adult women, primarily in the postmenopausal state. Absolute restrictions apply to patients with androgen-dependent cancers, certain severe cardiovascular/renal conditions, and use during pregnancy or lactation. Conditional eligibility requires that patients with heart, liver, or kidney diseases must be monitored closely, as mandated by the regulatory authority.

The official regulatory profile for AndroFeme, which contains the active ingredient Testosterone, documents specific interaction patterns with other medicinal products, primarily categorized by pharmacodynamic and exposure-altering effects.

Documented Drug Interactions

1. Oral Anticoagulants Co-administration with oral anticoagulants, such as Warfarin, can alter their activity. This interaction necessitates frequent monitoring of the patient's International Normalized Ratio (INR) and prothrombin time as a procedural constraint to ensure safe coagulation management.

2. Antidiabetic Agents Testosterone may result in a decrease in blood glucose levels, which can lead to a decreased requirement for antidiabetic agents, including Insulin. This pharmacodynamic effect requires adjustment consideration for the co-administered medication.

3. Corticosteroids and ACTH Concurrent use with Corticosteroids or Adrenocorticotrophic Hormone (ACTH) may increase the risk of fluid retention (edema). Regulatory documentation specifies that this interaction requires particular caution in patients with pre-existing cardiac, renal, or hepatic disease.

Interaction Context Constraints

The regulatory labeling does not cite any specific drug-drug combinations that are formally classified as contraindicated, nor are any mandatory dose separation timing rules documented for systemic medications. The documented interaction structure focuses on establishing procedural constraints requiring enhanced clinical or laboratory monitoring to manage the altered effects of co-administered medicines.

Testosterone, the active pharmaceutical ingredient in AndroFeme, functions as an agonist at the androgen receptor (AR), a ligand-activated nuclear receptor predominantly expressed in target tissues such as skeletal muscle, bone, and adipose tissue.

---

Upon traversing the cell membrane, testosterone binds to the cytosolic AR, causing a conformational change, dissociation from heat shock proteins, and translocation of the activated ligand-receptor complex into the cell nucleus. Within the nucleus, the AR complex acts as a transcription factor, binding to specific DNA sequences known as Androgen Response Elements (AREs) in the promoter regions of target genes. This binding event modulates gene transcription, either increasing or decreasing the synthesis of specific messenger RNA (mRNA) transcripts.

---

Downstream cascades involve the altered expression of proteins responsible for cellular anabolism, nitrogen retention, and erythropoiesis. This molecular modulation ultimately leads to system-level physiological consequences, including changes in bone mineral density, lean body mass accrual, and hematocrit levels.

Official Administration Guidelines for AndroFeme (Testosterone) 1% Cream

AndroFeme is a transdermal cream containing 1% w/v testosterone, and its use is guided by established clinical protocols. The proper use protocol involves precise dosing, application technique, and hygiene.

Administration Feature	Official Instruction
Route & Site	Transdermal application to clean, dry skin on the upper outer thigh or buttock.
Dosing Schedule	The recommended starting dose is 0.5 mL of cream (5 mg testosterone) once daily. The dose may be increased up to a maximum of 1.0 mL (10 mg) daily, based on blood test results and clinical response.
Preparation	The prescribed dose must be accurately measured using the graduated applicator provided. The cream should be massaged evenly into the skin until absorbed (about 30 seconds).
Timing & Frequency	Apply the cream once daily at approximately the same time each day to maintain consistent testosterone levels.

Procedural and Safety Measures

To ensure proper use and prevent unintended transference of the hormone, several steps are followed. Patients must wash their hands thoroughly with soap and water after each application. They must also cover the application area with clothing once the cream is dry to prevent skin-to-skin contact with others. Bathing, showering, or swimming should be avoided for at least four hours after application. Do not apply the cream to the genital area or to broken or damaged skin. If a dose is missed, apply it as soon as remembered, but skip it and resume the normal schedule if it is almost time for the next dose; never apply a double dose. Use is typically reviewed after three to six months, and treatment should be ceased if no benefit is experienced by six months.

Research evidence / Overview of studies for AndroFeme (Testosterone)

Evidence for Use in Hypoactive Sexual Desire Disorder (HSDD)

Research examining the use of transdermal testosterone cream in women has primarily been conducted using randomized controlled trials (RCTs). These studies were applied in research contexts involving postmenopausal women diagnosed with Hypoactive Sexual Desire Disorder (HSDD), a condition marked by functional limitations and distressing loss of sexual desire. Studies examined endpoints such as the frequency of satisfying sexual events (SSEs) recorded over defined time intervals when comparing the medicine against a placebo.

Comparison to Placebo and Study Design

The main clinical trials were designed to be double-blind and placebo-controlled. The design of these studies was used to evaluate patient-reported experience when comparing the active medicine versus an inactive product. Research monitored measurements of change in the frequency of satisfying sexual events, which was one of the core outcomes examined during the study period. Studies reported measurements detailing how symptoms evolved in the observed populations during these short-term trials.

Long-Term Studies and Follow-Up Duration

Studies exploring symptom changes over time typically involved follow-up durations that were limited to the short-term, such as three to six months for primary effectiveness endpoints. Evidence derived from settings with varying symptom burdens was observed across intermediate follow-up periods, with safety monitoring continuing for up to two years (24 months) in some observational settings evaluating daily-life functioning.

Evidence in Specific Patient Populations

The results apply primarily to the populations studied: postmenopausal women. Research describes patient-reported outcomes when the medicine was used in women concurrently receiving estrogen therapy. Limited data are still emerging for certain groups, such as women at high cardiometabolic risk, who were frequently excluded from the clinical trials due to safety concerns. Data for premenopausal women remain insufficient, as studies focused on postmenopausal women.

Research on Non-Sexual Outcomes (Mood, Cognition, Bone Health)

Studies monitored how symptoms evolved across a range of secondary outcomes related to systemic or functional imbalance, including mood, cognitive function, and bone mineral density (BMD). Findings were mixed and often inconsistent when examining these outcomes. The data are still emerging, and research provides limited insight into these areas.

What is Still Uncertain About the Research

Research contributes to the broader evidence landscape but does not provide individual predictions, and key research limitation frames apply to the current body of evidence. Long-term outcomes are not fully established, particularly for safety and cardiovascular outcomes over many years of use. Data for certain groups, such as women who are premenopausal, remain insufficient.

Key Studies & References

1. ANDROFEME 1 testosterone 1% w/v (10 mg/mL) cream tube (324274) - Australian Register of Therapeutic Goods (ARTG) Summary
2. Testosterone Therapy for Postmenopausal Women: Efficacy and Safety - Hormone Balance (Review summarizing evidence on sexual function, well-being, cognition, bone health, and safety data limitations)

Common questions about AndroFeme (Testosterone) (FAQ)

---

Q: How quickly do people typically start to notice the effects of AndroFeme?

Clinical studies often involve follow-up periods of three to six months to evaluate the primary effectiveness of the medicine. Official guidance specifies that treatment is typically reviewed at six months, and cessation may be considered if no clinical benefit is experienced by this timeframe. Regulatory review periods suggest that treatment efficacy is formally assessed after several months of use.

---

Q: Can men use AndroFeme for testosterone deficiency?

Official regulatory documents clearly state that male patients are an absolute contraindication for this specific product. AndroFeme is a preparation that is manufactured and licensed specifically for use in the female population.

---

Q: Can this medication affect my cholesterol levels?

Regulatory warnings for testosterone-class products note that treatment may lead to changes in blood lipid profiles, which includes cholesterol levels. For this reason, official protocols document that lipid concentrations should be monitored periodically through blood tests during therapy.

---

Q: Is AndroFeme a controlled substance, and what does that mean?

The active ingredient, testosterone, is classified as a Controlled Substance in many regions, such as Schedule III in the United States. This legal classification is based on the substance's potential for misuse, which may result in additional restrictions on how the medicine can be prescribed, supplied, and handled.

---

Q: Does AndroFeme impact fertility, based on official safety information?

For women who are premenopausal, official safety documents describe that treatment may lead to changes in the reproductive system. These effects can include the cessation of ovulation and the menstrual periods.

---

Q: Is AndroFeme the same as other testosterone products like gels or patches?

No, official labeling for testosterone products notes that different topical preparations—such as creams, gels, and patches—may have different doses and strengths. These variations can result in different levels of systemic absorption, even if the active ingredient is the same.

---

Q: What happens if I forget to apply the cream?

The official protocol is to apply a missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled application, the user is instructed to skip the forgotten dose and resume the regular schedule. Regulatory guidance specifies that a double dose should never be applied.

---

Q: Are there any common reasons why AndroFeme might be stopped after starting it?

Official administration guidelines specify that treatment should be ceased if no clinical benefit is experienced after approximately six months. Treatment is also typically discontinued if significant side effects, particularly signs of excessive androgen exposure, occur.

---

Q: Does AndroFeme cause mood changes or emotional side effects?

Regulatory documents for the testosterone class often include reports of mood swings and irritability among the documented side effects. Official information indicates that emotional changes are associated with androgen therapy.

---

Q: Are there foods or supplements that might interact with AndroFeme?

Official guidance on testosterone products generally suggests that patients consult with a healthcare professional regarding the use of their medicine with food, alcohol, or supplements. This is because certain herbal products, such as Licorice, may be noted in some regulatory documents as potential sources of interaction.

---

Q: Is AndroFeme an approved treatment for low libido in all patients?

The evidence supporting the medicine's effectiveness primarily applies to postmenopausal women diagnosed with Hypoactive Sexual Desire Disorder (HSDD). Official research documents state that data for other patient populations, such as premenopausal women, are insufficient.

---

Q: What if I have an allergic reaction to one of the ingredients in the cream?

Official patient information states that immediate medical attention should be sought for symptoms indicative of a severe allergic reaction. These symptoms may include difficulty breathing or significant swelling of the face, lips, tongue, or throat.

---

Q: Will I need regular blood tests while using AndroFeme?

Yes, official administration protocols require follow-up blood tests at specified intervals. This monitoring is necessary to adjust the dose for effectiveness and safety, ensuring testosterone levels remain within the accepted female physiological range.

---

Q: Why is it important to apply the cream to specific areas of the body?

Regulatory documents specify application to sites like the upper outer thigh or buttock because these areas were studied in clinical trials. This specificity helps ensure consistent and optimal systemic absorption of the medicine while minimizing the risk of unintentional transfer to other people.

---

Q: What are the eligibility criteria for AndroFeme as described by authoritative bodies?

Official eligibility is determined by licensing, which restricts use to adult women, primarily in the postmenopausal state, who have a diagnosed hormone deficiency. Absolute restrictions apply to patients with certain cancers or during pregnancy and breastfeeding.

---

Q: Does official research cover the use of AndroFeme in patients over 65?

Official documents advise caution for patients over 70 years of age. While study populations often include postmenopausal women, the safety and efficacy have not been specifically established or fully detailed for the general population over 65.

---

Q: Is there a maximum length of time AndroFeme is described to be used?

Official research data on effectiveness is limited to short-term trials of a few months, with safety monitoring sometimes extending up to two years. Regulatory information notes that long-term outcomes over many years of continuous use are not fully established.

---

Q: Can AndroFeme affect sleep patterns or cause insomnia?

Regulatory warnings for testosterone products note that treatment may potentiate or worsen sleep apnea in some patients. This is especially true for individuals with pre-existing risk factors. Regulatory documents indicate that monitoring for changes in breathing during sleep may be relevant.

---

Q: Why is it necessary to measure testosterone levels before and during treatment?

Regulatory guidance mandates testing before treatment to verify a diagnosis of deficiency. Subsequent testing is required to adjust the dose, ensuring the achieved testosterone levels are both effective and remain within the normal physiological range for women.

---

Q: Are the benefits of AndroFeme supported by multiple clinical trials?

The research evidence overview refers to the use of transdermal testosterone in women being primarily conducted using randomized controlled trials (RCTs). These studies were used to evaluate the medicine’s effectiveness by comparing it against a placebo.

---

Q: How is the safety profile of AndroFeme described for individuals with diabetes?

Regulatory documents advise that the medicine should be used with caution in patients with diabetes mellitus, particularly due to the potential for fluid retention. Testosterone may also affect blood glucose, which could require the adjustment of antidiabetic medicines.

---

Q: Are there different strengths of AndroFeme available?

Official product documentation refers to a single available strength: AndroFeme 1% w/v cream. The dose prescribed is adjusted by varying the volume of this single strength cream that is applied (e.g., between 0.5 mL and 1.0 mL).

How to Store and Dispose of AndroFeme (Testosterone) Cream

Official regulatory guidelines establish specific requirements for the storage, handling, stability, and disposal of AndroFeme cream to ensure product integrity and safety.

Storage Conditions

Requirement	Condition
Temperature	Store below 25 C in a cool, dry place.
Protection	Protect from heat, direct sunlight, and moisture.
Prohibited	Do not freeze or store in the bathroom, car, or on window sills.

Handling and Stability

The cream must be kept out of the reach of children at all times. Once the sealed tube is opened, the product is stable and should be used within 12 weeks. The cap must be replaced firmly after each use. Patients are instructed not to transfer the cream out of the original tube and to wash hands thoroughly with soap and water after application.

Disposal

Consult a pharmacist for instructions on the correct and safe method for the disposal of any unused, leftover, or expired AndroFeme cream.